← Vanda Pharmaceuticals Inc. (VNDA) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
Vanda Pharmaceuticals Inc. (VNDA)
Pharmaceutical Preparations · market cap $307M · as of 2026-07-09
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-10-15 (est.)
Phase 2
Pipeline
20
programs
Upcoming events
5
next 90d+
Dossier
Ready
cached
Vanda Pharmaceuticals (VNDA) is a small-cap specialty pharma with 368 employees, a $384M market cap, and a sprawling pipeline of repurposed and novel CNS/dermatology/GI assets spanning Phase 2–3. The company carries ~$54M cash against a reported 3.2-month runway, generating meaningful revenue (~$216M in 2025) primarily from its approved tasimelteon franchise (Hetlioz), but posted a $220M net loss in 2025, a sharp deterioration from prior years. Key near-term binary events include Phase 3 readouts for tradipitant (motion sickness, Dec 2026), VQW-765 (performance anxiety, Dec 2026), and a PDUFA date for imsidolimab (generalized pustular psoriasis, Jan 2027).
The catalyst path
- 2026-10-15 (est.)Phase 2 · iloperidoneimp 7/10
- 2026-11-04 (est.)Earningsimp 5/10
- 2026-12-01 (est.)Phase 3 · Tradipitantimp 9/10
- 2026-12-15 (est.)Phase 3 · VQW-765imp 9/10
- 2027-09-30 (est.)Phase 3 · Tradipitantimp 9/10
Pipeline
| Asset | Phase | Indication |
|---|---|---|
| Tasimelteon Oral Suspension | Phase 3 | Insomnia Disorder |
| Ponesimod | Phase 3 | Moderate-to-severe Chronic Plaque Psoriasis |
| Imsidolimab | Phase 2 | Acne Vulgaris |
| 20 mg VEC-162 | Phase 3 | Insomnia |
| VEC-162 20 mg | Phase 3 | Primary Insomnia |
| Trichostatin A | Phase 2 | Onychomycosis of Toenail |
| Tradipitant | Phase 3 | Motion Sickness |
| VSF-173 | Phase 2 | Excessive Somnolence |
| Tasimelteon Oral Capsule, Tasimelteon Liquid Suspension | Phase 3 | Autism Spectrum Disorder |
| Ziprasidone | Phase 3 | Schizophrenia |
| VLY-686 (Tradipitant) | Phase 2 | Gastroparesis |
| Tasimelteon | Phase 3 | Sleep Wake Disorders |
| Milsaperidone | Phase 3 | Major Depressive Disorder (MDD) |
| VCA-894A | Phase 2 | Charcot Marie Tooth Disease (CMT) |
| iloperidone | Phase 3 | Schizophrenia |
| Open Label Tradipitant | Phase 3 | Idiopathic Gastroparesis |
| VLY-686 | Phase 2 | Treatment-resistant Pruritus Associated With Atopic Dermatitis |
| Imsidolimab high dose | Phase 3 | Generalized Pustular Psoriasis |
| VQW-765 | Phase 3 | Performance Anxiety |
| VEC-162 | Phase 2 | Circadian Rhythm Sleep Disorders |
Price & technical context
3-month
-22.5%
6-month
-32.0%
12-month
-5.7%
52-wk range
$4.32–$9.56
vs 50-day MA
-7.4%
vs 200-day MA
-26.5%
Realized vol
83.0%
Max drawdown
-49.7%
Daily closes through 2026-10-01. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for VNDA (10-K, 10-Q, S-3, 13D/G, Form 4)
- Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.